Sequenom — Investor Day (September 2015)
109 slides from Sequenom's investor day presentation, Sep 28, 2015
Slide 1: Investor + Analyst Day
INVESTOR + ANALYST DAY September 28, 2015
Slide 2: Welcome
Welcome Dirk van den Boom, PhD Interim President and CEO Chief Scientific & Strategy Officer
Slide 3: Forward-looking statements
Forward-looking statements Except for historical information, matters set forth in this presentation, including statements regarding Sequenom’s plans, potential, opportunities, financial or other expectations, projections, goals, objectives, milestones, strategies, market growth, timelines, product
Slide 4: Today's agenda
Today’s agenda Opening remarks Dirk van den Boom Corporate vision + overview Dirk van den Boom Reproductive health + genetic testing Mathias Ehrich, Rob Lozuk Coffee break Oncology Mathias Ehrich, Daniel Grosu Closing remarks Dirk van den Boom
Slide 5: Speakers
Speakers Mathias Ehrich, MD Rob Lozuk Daniel Grosu, MD Senior Vice President, Senior Vice President, Senior Vice President, Research and Development Commercial Operations Chief Medical Officer
Slide 6: Corporate vision and overview
Corporate vision and overview
Slide 7: Sequenom: positioning for 2020
Sequenom: positioning for 2020 Prenatal market is rapidly evolving creating both challenges and opportunities Recent performance does not reflect Sequenom’s potential Entire organization understands the challenges Sequenom is focused on driving value, leading innovation, and creating a sustainable b
Slide 8: Performance to date
Performance to date Launched three new laboratory-developed tests, VisibiliT™ in the United States, HerediT® UNIVERSAL To date results: and MaterniT GENOME™ Total Net earnings revenues of of $5.3 $70.6 million, million, including including $21 $ 4.0 million million gain in from license Illumina reve
Slide 9: Providing unique insights into your health all starts with a simple blood draw…
Providing unique insights into your health all starts with a simple blood draw…
Slide 10: Our vision
Our vision Interpreting the genome to improve your life
Slide 11: Sequenom's distinction
Sequenom’s distinction Innovator Committed to excellence. Responsible for new standard for noninvasive prenatal testing and the largest new global diagnostic category. Trusted Peer-reviewed publications and transparency in medical education, billing and commercialization. Comprehensive Most advanced
Slide 12: Sequenom evolution
Sequenom evolution Research to commercial [ 2014 ] NIPT innovator Focused operation NIPT licensing pools Discovery/clinical validation of Divested biosciences business Established global patent pool NIPT1 with Illumina for broad NIPT Launched MaterniT21 technology access laboratory-developed test (L
Slide 13: Reproductive health
Reproductive health High risk pregnancies MaterniT21® PLUS Market opportunity Invasive procedures Noninvasive prenatal test Annual births 97% of procedures have normal Laboratory-developed test 750K high-risk US births annually results (LDT) to identify pregnancies at 3.5M average risk US births Cos
Slide 14: Trusted clinical partners
Trusted clinical partners Sequenom performance “3 out of 4 maternal “MaterniT21 PLUS is “Clinicians ranked MaterniT21 fetal medicine recommended by PLUS higher than its competitors specialists use 84% of clinicians – in the 2 categories that matter MaterniT21 PLUS.” more than any other most to clini
Slide 15: Multi-pronged business model
Multi-pronged business model Embracing partnerships to enable adoption Doctors / Industry-leading, large-scale, next-generation sequencing patients / clinical laboratories labs • Serving 3,000+ doctors and 37 lab partners Processed over 500,000 genomic tests Sequenom / Licensing partnerships Illumin
Slide 16: Operating in large markets
Operating in large markets Addressable worldwide market opportunities by 2020 $14B $21B Oncology detection Sequenom Addressable Market $2B Oncology Carrier $2B profiling $3B NIPT Prenatal Other reproductive Oncology Oncology Addressable testing health profiling detection market
Slide 17: Translating to results
Translating to results Over $500M revenues by +$50M/yr NIPT test fees and royalties, with continued adoption of pooled patent globally and NIPT growth in international Oncology markets Patents extend beyond 2030 NIPT Liquid biopsy franchise in cancer profiling Royalty and detection Other 2020 revenu
Slide 18: Growth drivers
Growth drivers Products for growth Reproductive health Growing desire for complete karyotype level genomic health information Burgeoning demand for average risk screen for base chromosomal aneuploidies Broad international growth opportunities Liquid biopsy in oncology Therapy profiling / monitoring
Slide 19: Key takeaways
Key takeaways Innovation Trusted clinical Strong product Focused leader partner pipeline execution Provides innovative Products and practices Addresses major unmet Growing top-line solutions to the most trusted by physicians, needs and aims to revenue through a pressing and complex patients, and pay
Slide 20: Reproductive health and genetic testing
Reproductive health and genetic testing Mathias Ehrich, MD Senior Vice President Research and Development
Slide 21: Reproductive health and genetic testing
Reproductive health and genetic testing
Slide 22: Care continuum
Care continuum Reproductive health and genetic testing Pre-pregnancy “I want to become pregnant.” Pregnancy “I am pregnant.” “Provider of choice” Post-pregnancy “Is my baby healthy?
Slide 23: Leaders in noninvasive prenatal testing
Leaders in noninvasive prenatal testing Shaping the field First to show robust clinical validation with over 200 trisomy 21 samples First to create robust, high-throughput clinical laboratory using next generation sequencing First to market in noninvasive prenatal testing using cell-free DNA with br
Slide 24: Leading in scientific breakthroughs
Leading in scientific breakthroughs Sequenom accomplishments Breakthrough innovations Foundational technology for all current NIPT Cell-free fetal DNA in maternal blood Next-generation sequencing of circulating cell-free DNA (ccfDNA) allows for accurate identification of fetal chromosomal abnormalit
Slide 25: Leading in innovation
Leading in innovation Sequenom accomplishments R&D advances Pioneering biochemistry and bioinformatics solutions Detection of balanced translocations High accuracy at low no-call rates Industry leading low false positive rates for reporting of sub-chromosomal events Genome-wide analysis of deletions
Slide 26: Leading through responsible innovation
Leading through responsible innovation Foundational technology Breakthrough innovations Leading clinical validation Leading clinical performance
Slide 27: Leading through responsible innovation
Leading through responsible innovation
Slide 28: Leading laboratory performance
Leading laboratory performance Sequenom accomplishments Clinical performance Consistent Consistent high low no-result sensitivity rate and (?1.2%) high specificity Consistent fast turn-around time (5.2 calendar days) MaterniT21® MaterniT21® Relative Chr PLUSreportedcases as PLUS reported cases sensi
Slide 29: Case study; discordant trisomy test results
Case study; discordant trisomy 18 test results Clinical presentation: 27 weeks GA AMA and ultrasound findings NIPT result: positive for trisomy 18 Other testing: Amnio FISH: negative Amnio karyotype: 46, XY, add (18)(p11.3) Amnio aCGH: 12 Mb gain of 18q11.1-12.1
Slide 30: Invasive diagnostic testing for aneuploidy should be available for all women
“Invasive diagnostic testing for aneuploidy should be available for all women, regardless of maternal age.” Screening for fetal chromosomal abnormalities ACOG Practice Bulletin 88, December 2007 Number 77, January 2007 Invasive prenatal testing for aneuploidy Number 88, December 2007
Slide 31: Key innovations
Key innovations
Slide 32: Contextualizing cytogenetic abnormalities
Contextualizing cytogenetic abnormalities Trisomy Chromosome 21 Down Syndrome Sub-chromosomal abnormality 4p- Chromosome 4 Wolf Hirschhorn Syndrome ggc.usg.edu/wiki/Down_Syndrome 13
Slide 33: Why genome-wide content matters
Why genome-wide content matters Of 452,901 pregnancies in California… T21—50% Current NIPT T18—13% (T21/18/13 and SCA) misses > 20% T13—5.5% of total cytogenetic abnormalities Sex chromosome aneuploidy—10% Triploidy—2.6% Other trisomy + ~1/1000 fetuses Robertsonian—4.4% show a sub chromosomal Other
Slide 34: Leading through responsible innovation
Leading through responsible innovation
Slide 35: Leading laboratory performance
Leading laboratory performance Positive predictive value (PPV) matters to clinicians and patients Laboratories Sequenom™1 Illumina®2 (22q experience Natera™ only)2 Samples analyzed for microdeletions 175,393 14,353 21,948 Abnormal results reported 55 29 97 Confirmed true positives 40 5 12 Confirmed
Slide 36: Unmet needs for broad genome-wide coverage
Unmet needs for broad genome-wide coverage A key opinion leader’s perspective Ronald J. Wapner, MD Board-certified in Maternal-Fetal Medicine and Obstetrics and Gynecology New York-Presbyterian/Columbia
Slide 37: Shifting paradigm
Shifting paradigm Genome-wide detection of larger cytogenetic abnormalities (> 7Mb events) T21 risk Microdeletion risk 20 25 30 35 40 45 50 “A twenty year old woman’s risk of having one of those major chromosome abnormalities would be less than 1/1000; however their risk of having a microdeletion is
Slide 38: Shifting paradigm
Shifting paradigm Genome-wide detection of larger cytogenetic abnormalities (> 7Mb events) Identification of clinically relevant sub-chromosomal aberrations otherwise missed by NIPT Aids in assessment of potential pregnancy complications/ risk of adverse events Early recognition can change pre- and
Slide 39: Genome-wide vs targeted analysis
Genome-wide vs targeted analysis Genome-wide analysis Every chromosome analyzed Most comprehensive NIPT to date Allows for expanded clinical information without adding additional “targets” Targeted analysis Limited to only target regions of specific chromosome/ chromosome positions Higher failure ra
Slide 40: Leading through responsible innovation
Leading through responsible innovation
Slide 41: Genome-wide content
Genome-wide content oly = =— Matermnil = —___ ——— @ "s Gays
Slide 42: Analyzed chromosomal regions
Analyzed chromosomal regions Coverage for MaterniT™ GENOME vs. competitors MaterniT GENOME analyzes every chromosome and provides distinct results for: Any trisomy or monosomy Sex chromosome aneuploidy Existing select seven microdeletions Deletions or duplications ? 7Mb Unbalanced translocations ? 7
Slide 43: Validating MaterniT GENOME
Validating MaterniT™ GENOME in silico 01simulation Based on chromosomal events in the ClinGen Structural Variant Working Group database > 2.6 million cases simulated Model mixtures gDNA mixtures + “spike-in” cfDNA samples to validate performance > 960 gDNA mixtures used cfDNA samples Use of > 1000 e
Slide 44: Validating MaterniT GENOME
Validating MaterniT™ GENOME Clinical validation results Blinded case-control study with > 1000 plasma samples from pregnant women. Results confirm high sensitivity and specificity
Slide 45: Why genome-wide content matters
Why genome-wide content matters Of 452,901 pregnancies in California… Current NIPT (T21/18/13 and SCA) misses > 20% of total cytogenetic abnormalities 1. Norton, M. Cell free DNA analysis vs. sequential screening as primary testing considering all fetal chromosomal abnormalities. Presented at Societ
Slide 46: Why genome-wide content matters
Why genome-wide content matters Of 452,901 pregnancies in California… Genome wide NIPT covers 95% of cytogenetic abnormalities and select microdeletions 1. Norton, M. Cell free DNA analysis vs. sequential screening as primary testing considering all fetal chromosomal abnormalities. Presented at Soci
Slide 47: Leading test portfolio
Leading test portfolio Leveraging a proven and validated technology T21, T18, gender T21, T18, T13, Genome-wide testing SCA, ESS for CNVs > 7 Mb, Result reported as selected MDs risk score Result reported as positive, negative, Result reported as additional findings positive, negative The VisibiliT™
Slide 48: Take-home messages
Take-home messages Shaping the future of NIPT Best-in-class technology Robust product portfolio spanning high content needs and cost effective requirements Continuous and responsible innovation
Slide 49: Reproductive health and genetic testing
Reproductive health and genetic testing Rob Lozuk Senior Vice President Commercial Operations
Slide 50: Commercial execution
Commercial execution
Slide 51: Size of opportunity
Size of opportunity US increased risk and average risk births 3.5M births1 750K births1 US high risk US average births risk births 1. Martin JA, et al. Division of Vital Statistics. Births: Final data for 2013. National Vital Statistics Reports. 2013;62(9). 3 Online at http://www.cdc.gov/nchs/births
Slide 52: Size of opportunity
Size of opportunity Highlights of major regions offering NIPT 80M+ births2 1.5M NIPT Current Regions offering penetration NIPT $3+ billion total NIPT market opportunity worldwide1 1. 2. Morgan Stanley Research, NIPT Competition Evolves, December 2, 2014. Citi Research, Life Science Tools and Diagnos
Slide 53: NIPT market drivers
NIPT market drivers The traditional view of the market is changing HIGH RISK AVERAGE RISK Large; growth continues Emerging market segment Advanced maternal age original Physician and patient demand driver of prenatal testing for chromosomal abnormalities Global societies support Traditionally T21, T
Slide 54: Market dynamics
Market dynamics NIPT future evolution
Slide 55: Positioned to serve the MFM + OB customer groups
Positioned to serve the MFM + OB customer groups Growing our reproductive health franchise Large whole-genome Broad and differentiated sequencing footprint product portfolio Comprehensive Focused commercial customer solutions organization Trusted partner Enabling the global market
Slide 56: Large whole-genome sequencing footprint
Large whole-genome sequencing footprint Broad and differentiated product portfolio Comprehensive customer solutions Focused commercial organization Trusted partners Enabling the global market
Slide 57: Large whole-genome sequencing footprint
Large whole-genome sequencing footprint Sequenom Laboratories CAP-accredited First clinical Capacity to + CLIA-certified laboratory to accommodate molecular operationalize significant diagnostics and scale NGS growth laboratories
Slide 58: Large whole-genome sequencing footprint
Large whole-genome sequencing footprint Broad and differentiated product portfolio Comprehensive customer solutions Focused commercial organization Trusted partners Enabling the global market
Slide 59: Our portfolio today
Our portfolio today Comprehensive reproductive health franchise to service the MFM and OB communities Carrier HerediT screen ® UNIVE that d Genome-wide MaterniT™ GENOME fetal aneuploidies > 250 disorders HerediT Carrier screen ® CF that MaterniT21® PLUS Select fetal aneuploidies detects > 136 cystic
Slide 60: Changing the game
Changing the game Unmet needs Occurrence of sub-chromosomal abnormalities is independent of maternal age Societies show appreciation for information not seen in conventional screening More content Identifies >95% of chromosomal anomalies No other competitor comes close Differentiation Industry leadi
Slide 61: Broad and differentiated product portfolio
Large whole-genome sequencing footprint Broad and differentiated product portfolio Comprehensive customer solutions Focused commercial organization Trusted partners Enabling the global market
Slide 62: Patient experience
Patient experience Our focus is multi-faceted and a high priority in the business
Slide 63: Comprehensive customer solutions
Large whole-genome sequencing footprint Broad and differentiated product portfolio Comprehensive customer solutions Focused commercial organization Trusted partners Enabling the global market
Slide 64: MFM commercial organization
MFM commercial organization Historical approach to the market was successful 110+ f nnel Product portfolio Logistics Reproductive health tests NPS survey score 92 addressing MFM needs (-100 to +100 scale)1 Billing Customer service MaterniT21 MaterniT GENOME PLUS National Genetic counselors accounts
Slide 65: Broad NIPT adoption via OB/GYN channel
Broad NIPT adoption via OB/GYN channel
Slide 66: Organization structured by customer segment
Organization structured by customer segment MFM and OBGYN dedicated team Grow reach, frequency 110+ fi nel Product portfolio + utilization Scale Structured as market by call dictates point OBGYN Universal products carrier Simplify product mix Laser focus on screening + align to customer continued im
Slide 67: Focused commercial organization
Large whole-genome sequencing footprint Broad and differentiated product portfolio Comprehensive customer solutions Focused commercial organization Trusted partners Enabling the global market
Slide 68: Breadth of coverage partners
Breadth of coverage 37 partners 200M+ 44M Global partners US commercial lives US government-funded across 44 countries covered lives
Slide 69: In-network strategy
In-network strategy The value of an in-network provider Sequenom Stabilize Payers direct reimbursement care to in-network laboratories Allows for expansion as tests are offered Doctors Penalties Contractually and bound fee reductions to utilize with in-network use of out-of-network laboratories labs
Slide 70: Enabling the global market
Large whole-genome sequencing footprint Broad and differentiated product portfolio Comprehensive customer solutions Focused commercial organization Trusted partners Enabling the global market
Slide 71: Enabling the global market
Enabling the global market Leveraging patent pool agreement to enable NIPT globally Revenue realized with every test Substantial future value PATENT POOL CONTENT GLOBAL LICENSES The patent pool combines critical NIPT ? 32 organizations globally to data granted patents and patent applications license
Slide 72: Potential annual license revenue
Enabling the global market Potential annual license revenue Active partners Locations Annual licensing revenue 14 > 40 10 accts > 80 accts countries countries $6–10M $50M + Today Future Today Future Today Future
Slide 73: Key takeaways
Key takeaways Well positioned for future growth Unparalleled in-network footprint Expansive product portfolio and commercial focus that aligns to customer needs Commitment to the patient experience Numerous revenue streams that monetize the rapidly expanding global marketplace
Slide 74: Oncology
Oncology Mathias Ehrich, MD Senior Vice President Research and Development
Slide 75: Experience and expertise in oncology
Experience and expertise in oncology Sequenom milestones EpiTYPER® OncoCARTA™ UltraSEEK™ First in methylation First in mutation First in sensitivity Oncology expertise Sequenom oncology today Reproductive health experience MaterniT21® PLUS NIPT + cancer MaterniT™ GENOME First in NIPT First case Firs
Slide 76: Incidental NIPT finding
Incidental NIPT finding Patient presented at age High risk indication AMA Gestational age 10 weeks Normal genome profile May 2014 Profile Sept. 2014 Profile – after surgery differentiated adenocarcinoma, Stage II, 49 lymph nodes negative for metastasis
Slide 77: Patient story
Patient story Video Eunice Lee, M.D.
Slide 78: Case examples
Case examples Sequenom Laboratories 400,000 Data from Sequenom samples > 55% 18 of malignant malignant cases Laboratories previously unknown Altered Genomic alterations genomes prevent 40 “Non-reportable” cases samples, accurate NIPT reading patients and physicians decide follow-up
Slide 79: Case examples
Case examples Tumor types identified Uterine leiomyomas Solid tumors Hematological tumors 20 cases 9 cases 9 cases Benign smooth Breast, colon, Non-Hodgkin, Multiple muscle neoplasm angio-sarcoma, other myeloma, T-cell lymphoma, carcinoma CML, Hodgkin Key questions How do we have to Is this a lot of
Slide 80: Laboratory benchmark
Laboratory benchmark Cases of cancer detected in pregnant population 10 15 ~13 cases cases cases per per per 100,000 100,000 100,000 Lee, 2012 Eibye, 2013 Sequenom Australia Denmark R&D analysis* 1994—2008 1977—2006 2013—2015 *Note: R&D analysis based on research consented cohort of 78K
Slide 81: Challenge of ctDNA
Challenge of ctDNA 6000 600 6 copies copies copies cfDNA ctDNA Mutated ctDNA Only 6copies
Slide 82: Sequenom technology solution
Sequenom technology solution Proprietary biochemistry + bioinformatics = CodeBreaker™ 0.010 Raw data 0.008 0.010 0.006 CodeBreaker™ 0.004 0.008 0.002 0.010 Biochemistry 0.010 Bioinformatics 0.008 0.000 0.008 0.006 1293500 1294500 1295500 0.006 0.004 0.006 0.004 0.004 0.002 0.002 0.002 0.000 0.000 12
Slide 83: How do we do it?
How do we do it? EGFR T G Mutation Challenge The trick is not to find a needle in a haystack Detecting mutations is not difficult – they are readily visible The challenge is to differentiate sequencing errors from true mutations CodeBreaker™ Codebreaker organizes the sequence reads according to thei
Slide 84: Our product
Our product OncoPlasma™ – ctDNA detection + profiling assay for pan-cancer Metric OncoPlasma Total number of genes 134 measured OncoPlasma™ is designed for cancer patients afflicted with late stage (Stage Target limit of detection 0.1-1% III-Stage IV), non-hematological malignancies Target specifici
Slide 85: Genes in FDA / NCCN guidelines
Genes in FDA / NCCN guidelines Clinical relevance of gene targets Panel composition by genes Genes Indications ALK NSCLC FDA / BRAF NSCLC, melanoma NCCN BRCA1* Ovarian cancer 8% EGFR NSCLC Other ERBB2 Breast, gastric cancer cancer pathway KIT Melanoma genes 52% Clinical trials KRAS Colorectal cancer
Slide 86: OncoPLASMA in action
OncoPLASMA™ in action The power of Sequenom We asked a simple question: Can we find mutations in the cancer cases we have seen in the lab? We used the same library that was used for NIPT and ran it with OncoPLASMA.
Slide 87: OncoPLASMA in action
OncoPLASMA™ in action The power of Sequenom We found a TP53 mutation at 2.7% in this plasma 30k 900 seq mutated reads reads TP53 A99V This demonstrates the power of combining expertise in copy number and mutation analysis “P53” by Thomas Splettstoesser -Based on atomic coordinates of PDB 1TUP, rende
Slide 88: Colon cancer case study
Colon cancer case study Colon cancer stage IV (T3N1M1) BRAF V600E BRAF V600E mutation indicating sensitivity for proteasome inhibitors (Vemurafenib) Mutation frequency in: Tumor: 15% Tumor tissue Plasma DNA: 13% BRAF V600E Plasma Tumor profiling
Slide 89: Colon cancer case study
Colon cancer case study Colon cancer stage IV (T3N1M1) Plasma shows the tumor CNVs as well as the tumor mutations Copy number variations indicate that ~20% of the tumor is genetically abnormal Tumor genetics likely heterogeneous (chr6del) BRAF V600E mutation indicating sensitivity for proteasome inh
Slide 90: Market opportunity for early detection cancer
Market opportunity for early detection cancer Copy number variations and mutations are important CNVs Mutation Copy number analysis is unique to Sequenom
Slide 91: Market opportunity for early detection cancer
Market opportunity for early detection cancer The addition of DNA methylation analysis can provide superior results CNVs Mutation Sequenom has world-leading expertise in DNA methylation analysis: Tech + application development Methylation Functional research in developmental biology Fetal fraction p
Slide 92: Market opportunity for early detection cancer
Market opportunity for early detection cancer These programs can potentially be targeted towards CNVs Mutation • General population screening for colon cancer Follow-up testing for node positive CT scan in lung cancer screening Methylation Or general cancer recurrence monitoring
Slide 93: Another cancer case study
Another cancer case study What plasma can do in early detection One more exciting example Tumor shows numerous copy number variations Plasma confirms presence of low levels of tumor DNA Tumor tissue • Lung cancer stage 1a Plasma
Slide 94: Oncology
Oncology Daniel Grosu, MD Senior Vice President, Chief Medical Officer
Slide 95: Sequenom liquid biopsy collaboration
Sequenom liquid biopsy collaboration A key opinion leader’s perspective Eric Topol, M.D. Chief Academic Officer, Scripps Health Director, Scripps Translational Science Institute
Slide 96: Diversity of cancer
Diversity of cancer One name… many diseases Glioblastoma Lung adenocarcinoma Breast 200+ types of cancer Melanoma Colorectal Ovarian Uterine
Slide 97: Cancer touches nearly everyone
Cancer touches nearly everyone Huge societal and personal impact > 1.7 million 14.5 million 1 in 3 1 in 2 New cancer cases in People living with Americans will be Americans diagnosed the US annually cancer in the US diagnosed with cancer with cancer die from it American Cancer Society American Cance
Slide 98: Cancer is a very complex disease of the genome
Cancer is a very complex disease of the genome Tumor accessibility and heterogeneity—mitigated by liquid biopsy Lung metastases S1 S3 Chest-wall metastases S2 Primary tumor 10 cm Perinephric metastases LEGEND S Tissue Sample Identifier
Slide 99: Clinical utility of ctDNA along the patient journey
Clinical utility of ctDNA along the patient journey Detection & Profiling SIGNS & SYMPTOMS ADJUVANT TREATMENT NEO-ADJUVANT TREATMENT MORE TREATMENT DIAGNOSIS RECURRENCE SUB-CLINICAL DISEASE CURATIVE-INTENT SURGERY DETECTION: Presence & Burden of Disease PROFILING: Presence of Actionable Targets Scre
Slide 100: Clinical utility: detection
Clinical utility: detection Colorectal cancer screening example SIGNS & NEO-ADJUVANT ADJUVANT MORE SYMPTOMS TREATMENT TREATMENT TREATMENT SUB-CLINICAL DIAGNOSIS CURATIVE-INTENT RECURRENCE DISEASE SURGERY CLINICAL CONTEXT >130,000 new CRC cases per year in the US > 50% CRC cases diagnosed at later st
Slide 101: Clinical utility: detection
Clinical utility: detection Lung cancer screening example Stage at diagnosis Five-year relative survival rate Lung cancer Lung cancer 4% 15% 22% 56% 52% 24% LOCAL REGIONAL DISTANT LOCAL REGIONAL DISTANT Current lung cancer screening paradigm: computed tomography (CT) ~25% “suspicious findings”—to be
Slide 102: Clinical utility: profiling
Clinical utility: profiling Targeted treatment selection example Effectiveness of drugs by disease category Response (panitumumab) to EGFR blockade ANTIDEPRESSANTS 62% Mutant KRAS ASTHMA DRUGS 60% DIABETES DRUGS 57% ARTHRITIS DRUGS 50% Wild-type KRAS ALZHEIMER’S DRUGS 30% CANCER DRUGS 25% PR: partia
Slide 103: Clinical foundation
Clinical foundation Developing the clinical evidence base Translational research Clinical validation Colon cancer Profiling Lung cancer Detection Breast cancer Melanoma KOL SQNM Other studies Clinical studies Clinical Advisory Build clinical experience Board evidence for w/ leading future LDT cancer
Slide 104: Upcoming liquid biopsy RUO test
Upcoming liquid biopsy RUO test Pan-cancer profiling for actionable genomic alterations OncoPlasma family of Sequenom ™ is poised ctDNA to tests be the first of a Aimed at molecular profiling of later-stage solid tumors where biopsy is not feasible or cannot provide sufficient material for NGS panel
Slide 105: Product pipeline
Product pipeline Profiling and detection Oncology Research and product lines development Validation Commercial Cancer profiling $2B+ Multi-marker pan-cancer Market Opportunity translational applications by 2020 Cancer detection $14B+ Multi-marker pan-cancer Market detection panel for clinical Opport
Slide 106: Key takeaways
Key takeaways The Sequenom advantage Advanced biochemistry + bioinformatics Built upon extensive clinical expertise in oncology and NIPT Test for all classes of genomic alterations in cancer Point mutations Insertions + deletions Methylation Translocations Copy number variants Fragment size Clinical
Slide 107: Wrap-up
Wrap-up Dirk van den Boom, PhD Interim President and CEO Chief Scientific & Strategy Officer
Slide 108: Positioning for Growth
Positioning for Growth Positioned to capitalize on Average Risk market MaterniT™ GENOME paves the way for comprehensive information Opportunity for proprietary and potentially “kitable” assays in Oncology Significant opportunity in oncology through circulating tumor DNA detection and profiling New o
Slide 109: Dirk van den Boom, PhD Carolyn Beaver
Dirk van den Boom, PhD Carolyn Beaver Interim President and CEO Senior Vice President, Chief Scientific & Strategy Officer Chief Financial Officer Mathias Ehrich, MD Rob Lozuk Daniel Grosu, MD Senior Vice President, Senior Vice President, Senior Vice President, Research and Development Commercial Op